BridgeBio Pharma Inc (BBIO) — Strategic Asset Allocation Index
BridgeBio Pharma Inc (BBIO) has a Strategic Asset Allocation Index of 18.8% as of December 2020. Strategic assets (PP&E of $20.32 Million plus long-term investments of $0.00) total $20.32 Million, measured against net assets of $107.89 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. Check BBIO financial resilience to evaluate the company's liquid asset resilience ratio.
SAAI
Strategic Assets
PP&E
Net Assets
BridgeBio Pharma Inc Strategic Asset Allocation Index (2019–2020)
This chart shows how BridgeBio Pharma Inc's Strategic Asset Allocation Index has evolved across 2 annual periods from 2019 to 2020. As of December 2020, the index stands at 18.8%, representing strategic assets of $20.32 Million against net assets of $107.89 Million USD. See BridgeBio Pharma Inc leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
Annual Strategic Asset Allocation Index for BridgeBio Pharma Inc (2019–2020)
The table below presents the year-by-year Strategic Asset Allocation Index for BridgeBio Pharma Inc from 2019 to 2020, covering 2 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see how much is BridgeBio Pharma Inc worth.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2020 | 18.8% | $20.32 Million | $20.32 Million | $0.00 | $107.89 Million | ▲ +11.1 pp |
| 2019 | 7.7% | $36.77 Million | $5.62 Million | $31.14 Million | $475.98 Million | — |